These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 16703565)
1. Revisiting the specificity of the MHC class II transactivator CIITA in vivo. Otten LA; Leibundgut-Landmann S; Huarte J; Kos-Braun IC; Lavanchy C; Barras E; Borisch B; Steimle V; Acha-Orbea H; Reith W Eur J Immunol; 2006 Jun; 36(6):1548-58. PubMed ID: 16703565 [TBL] [Abstract][Full Text] [Related]
2. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768 [TBL] [Abstract][Full Text] [Related]
3. A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites. Arancibia-Cárcamo CV; Osawa H; Arnett HA; Háskova Z; George AJ; Ono SJ; Ting JP; Streilein JW Eur J Immunol; 2004 Feb; 34(2):471-80. PubMed ID: 14768052 [TBL] [Abstract][Full Text] [Related]
4. T cell expression of CIITA represses Th1 immunity. Park WS; Bae Y; Chung DH; Choi YL; Kim BK; Sung YC; Choi EY; Park SH; Jung KC Int Immunol; 2004 Oct; 16(10):1355-64. PubMed ID: 15351782 [TBL] [Abstract][Full Text] [Related]
5. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain. Itoh-Lindstrom Y; Piskurich JF; Felix NJ; Wang Y; Brickey WJ; Platt JL; Koller BH; Ting JP J Immunol; 1999 Sep; 163(5):2425-31. PubMed ID: 10452977 [TBL] [Abstract][Full Text] [Related]
6. Constitutive expression of CIITA directs CD4 T cells to produce Th2 cytokines in the thymus. Patel DR; Li W; Park JS; Sofi MH; Gourley TS; Hangoc G; Kaplan MH; Chang CH Cell Immunol; 2005 Jan; 233(1):30-40. PubMed ID: 15876426 [TBL] [Abstract][Full Text] [Related]
7. Mini-review: Specificity and expression of CIITA, the master regulator of MHC class II genes. LeibundGut-Landmann S; Waldburger JM; Krawczyk M; Otten LA; Suter T; Fontana A; Acha-Orbea H; Reith W Eur J Immunol; 2004 Jun; 34(6):1513-25. PubMed ID: 15162420 [TBL] [Abstract][Full Text] [Related]
8. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433 [TBL] [Abstract][Full Text] [Related]
9. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice. Xu Y; McDonald J; Perloff E; Butticè G; Schreiber BM; Smith BD Mol Immunol; 2007 Mar; 44(7):1709-21. PubMed ID: 16982097 [TBL] [Abstract][Full Text] [Related]
10. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins. Broxmeyer HE; Cooper S; Hangoc G; Chang CH Exp Hematol; 2006 Aug; 34(8):1078-84. PubMed ID: 16863914 [TBL] [Abstract][Full Text] [Related]
11. Attenuation of MHC class II expression in macrophages infected with Mycobacterium bovis bacillus Calmette-Guérin involves class II transactivator and depends on the Nramp1 gene. Wojciechowski W; DeSanctis J; Skamene E; Radzioch D J Immunol; 1999 Sep; 163(5):2688-96. PubMed ID: 10453010 [TBL] [Abstract][Full Text] [Related]
12. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation. Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831 [TBL] [Abstract][Full Text] [Related]
13. IFN regulatory factor-1 plays a central role in the regulation of the expression of class I and II MHC genes in vivo. Hobart M; Ramassar V; Goes N; Urmson J; Halloran PF J Immunol; 1997 May; 158(9):4260-9. PubMed ID: 9126988 [TBL] [Abstract][Full Text] [Related]
14. Deregulated MHC class II transactivator expression leads to a strong Th2 bias in CD4+ T lymphocytes. Otten LA; Tacchini-Cottier F; Lohoff M; Annunziato F; Cosmi L; Scarpellino L; Louis J; Steimle V; Reith W; Acha-Orbea H J Immunol; 2003 Feb; 170(3):1150-7. PubMed ID: 12538670 [TBL] [Abstract][Full Text] [Related]
15. MHC class II transactivator represses human IL-4 gene transcription by interruption of promoter binding with CBP/p300, STAT6 and NFAT1 via histone hypoacetylation. Zhou X; Jiang Y; Lu L; Ding Q; Jiao Z; Zhou Y; Xin L; Chou KY Immunology; 2007 Dec; 122(4):476-85. PubMed ID: 17645498 [TBL] [Abstract][Full Text] [Related]
16. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052 [TBL] [Abstract][Full Text] [Related]
17. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells. Radosevich M; Song Z; Gorga JC; Ksander B; Ono SJ Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3185-95. PubMed ID: 15326139 [TBL] [Abstract][Full Text] [Related]
18. TGF-beta1 and IFN-gamma cross-regulate antigen presentation to CD4 T cells by macrophages. Delvig AA; Lee JJ; Chrzanowska-Lightowlers ZM; Robinson JH J Leukoc Biol; 2002 Jul; 72(1):163-6. PubMed ID: 12101276 [TBL] [Abstract][Full Text] [Related]
19. Tumor-mediated down-regulation of MHC class II in DC development is attributable to the epigenetic control of the CIITA type I promoter. Choi YE; Yu HN; Yoon CH; Bae YS Eur J Immunol; 2009 Mar; 39(3):858-68. PubMed ID: 19224634 [TBL] [Abstract][Full Text] [Related]
20. TNF-alpha suppresses IFN-gamma-induced MHC class II expression in HT1080 cells by destabilizing class II trans-activator mRNA. Han Y; Zhou ZH; Ransohoff RM J Immunol; 1999 Aug; 163(3):1435-40. PubMed ID: 10415044 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]